Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8296877 | 0.91 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL333030 | 0.90 | SMN1; SMN2 (0.38) | SMN1; SMN2MEN1KMT2APOLBPKM | |
| SCHEMBL331756 | 0.90 | MEN1 (0.35) | SMN1; SMN2MEN1KMT2APOLBPKM | |
| SCHEMBL331351 | 0.87 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2APOLBPKM | |
| SCHEMBL332114 | 0.87 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1KMT2APOLBPKM | |
| SCHEMBL331689 | 0.86 | SMN1; SMN2 (0.38) | SMN1; SMN2MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL331776 | 0.85 | SMN1; SMN2 (0.43) | SMN1; SMN2MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL332149 | 0.84 | KDM4E (0.30) | — | |
| SCHEMBL331219 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2MEN1KMT2APOLBPKM | |
| SCHEMBL330524 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1KMT2APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| CN-1882591-B | 5, 7-diaminopyrazolo [4,3-d ] pyrimidines with PDE-5 inhibiting activity | PFIZER LTD | 2011-08-10 | — | — | CN | disclosed |
| CN-101362764-B | 5,7-diaminopyrazolo '4,3-d!pyrimidines with PDE-5 inhibiting activity | PFIZER | 2011-04-20 | — | — | CN | disclosed |
| CN-101362765-B | 5,7-diaminopyrazolo '4,3-d-pyrimidines with PDE-5 inhibiting activity | PFIZER | 2011-02-02 | — | — | CN | disclosed |
| EP-1689751-B1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LTD (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| US-7572799-B2 | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors | PFIZER INC (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572799-B2 | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors | PFIZER INC (US) | 2009-08-11 | — | — | US | disclosed |
| CN-101362765-A | 5,7-diaminopyrazolo '4,3-d!pyrimidines with PDE-5 inhibiting activity | PFIZER (US) | 2009-02-11 | — | — | CN | disclosed |
| CN-101362764-A | 5,7-diaminopyrazolo '4,3-d!pyrimidines with PDE-5 inhibiting activity | PFIZER (US) | 2009-02-11 | — | — | CN | disclosed |
| CN-1882591-A | 5, 7-diaminopyrazolo [4, 3-d ] pyrimidines with PDE-5 inhibiting activity | PFIZER LTD (US) | 2006-12-20 | — | — | CN | disclosed |
| US-20050245544-A1 | Novel pharmaceuticals | AMPLIFIED PROTEOMICS INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245544-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | SMN1; SMN2 2626/4885MEN1 702/4885KMT2A 4632/4885 |
| US-20090247539-A1 | Novel Pharmaceuticals | ABCB11, PCSK9, SLC10A1 | SMN1; SMN2 2626/4885MEN1 702/4885KMT2A 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.